52 results about "Renal inflammation" patented technology

A remedy and / or a preventive for a chronic disease which contains an EDG-2 antagonist. Because of binding to a subtype EDG-2 of LPA receptor, an EDG-2 antagonist is useful in treating and / or preventing chronic diseases (for example, diseases caused by the progress of chronic asthma, glomerular nephritis, obesity, arteriosclerosis, rheumatoid and atopic diseases) induced and made chronic by tissue cells whose proliferation is accelerated by LPA mediated by EDG-2.

A pharmaceutical composition is provided for treatment and prevention of a disease caused by expression of a gene controlled by NF-κB or ets. The composition comprises at least one decoy and a pharmaceutically acceptable carrier. The decoy is an NF-κB decoy, an ets decoy, or a chimera decoy of NF-κB and ets. The disease is cerebral aneurysm, cancer, Marfan's syndrome, aortic detachment, post-angioplasty restenosis, chronic articular rheumatism, asthma, atopic dermatitis, nephritis, renal failure, or plaque rupture. The pharmaceutically acceptable carrier may be a hydrophilic polymer.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

The invention discloses the use of a class of methyl salicylate glycoside compounds represented by the general formula (1) and pharmaceutically acceptable salts thereof in the preparation of medicines for preventing and / or treating systemic lupus erythematosus and its complications. In the present invention, methyl salicylate glycoside has the pharmacological effect of reducing the expression levels of autoantibodies and inflammatory factors in lupus mice and improving immune function; it has the effect of slowing down the pathological process of lupus arthritis; The pharmacological effect of immune complex deposition and improving renal function in lupus mice; it has the effect of protecting spleen function in lupus mice. Methyl salicylate glycosides are monomeric compounds extracted and separated from the traditional Chinese herbal medicine Dianbaizhu, which has the advantages of low toxicity, simple extraction process, and mature synthetic route; its raw material resources are vast, and it is easy to prepare in large quantities. With good application and development prospects, it is an ideal new type of traditional Chinese medicine monomer for the treatment of complications such as systemic lupus erythematosus and its immune dysfunction, lupus arthritis, lupus nephritis, and lupus spleen injury.